// App-Quantinova.ai

POS0308 (2022) : EFFECT OF GUSELKUMAB ON SERUM BIOMARKERS IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE COSMOS STUDY

Researchers

Presenter

  • G. Schett

Principal Investigators

  • W. Chen

  • S. Gao

  • S. D. Chakravarty

  • M. Shawi

  • F. Lavie

  • E. Theander

  • M. Neuhold

  • L. Coates

  • S. Siebert

Medical Centers

  • FAU Erlangen-Nürnburg, Internal Medicine 3, Erlangen, Germany

  • Janssen Research & Development, Raritan, United States of America

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America

  • Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America

  • Janssen Cilag Global Medial Affairs, Global Medial Affairs, Issy les Moulineaux, France

  • Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden

  • Janssen, Scientific Affairs, LLC, Zug, Switzerland

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

Locations

  • Germany

  • United States

  • France

  • Sweden

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved